[go: up one dir, main page]

NO20033541L - Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer - Google Patents

Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer

Info

Publication number
NO20033541L
NO20033541L NO20033541A NO20033541A NO20033541L NO 20033541 L NO20033541 L NO 20033541L NO 20033541 A NO20033541 A NO 20033541A NO 20033541 A NO20033541 A NO 20033541A NO 20033541 L NO20033541 L NO 20033541L
Authority
NO
Norway
Prior art keywords
type
phosphodiesterase inhibitors
muscle diseases
heart muscle
diseases
Prior art date
Application number
NO20033541A
Other languages
English (en)
Other versions
NO20033541D0 (no
Inventor
Arne Sutter
Thomas Ehring
Thomas Welge
Klaus-Otto Minck
Claudia Wilm
Michael Gassen
Hans-Michael Eggenweiler
Michael Wolf
Pierre Schelling
Norbert Beier
Joachim Leibrock
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20033541L publication Critical patent/NO20033541L/no
Publication of NO20033541D0 publication Critical patent/NO20033541D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen vedrører anvendelsen av fosfodiesteraseinhibitorer av type 4 til behandling av hj ertemuskelsykdommer.
NO20033541A 2001-02-12 2003-08-11 Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer NO20033541D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102811 2001-02-12
EP01119875 2001-08-17
PCT/EP2002/000320 WO2002072103A1 (en) 2001-02-12 2002-01-15 Use of type 4 phosphodiesterase inhibitors in myocardial diseases

Publications (2)

Publication Number Publication Date
NO20033541L true NO20033541L (no) 2003-08-11
NO20033541D0 NO20033541D0 (no) 2003-08-11

Family

ID=26076468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033541A NO20033541D0 (no) 2001-02-12 2003-08-11 Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer

Country Status (9)

Country Link
US (1) US20050070529A1 (no)
EP (1) EP1368035A1 (no)
JP (1) JP2004521928A (no)
KR (1) KR20040012720A (no)
CN (1) CN1235589C (no)
CA (1) CA2437932A1 (no)
HU (1) HUP0303181A2 (no)
NO (1) NO20033541D0 (no)
WO (1) WO2002072103A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102442941A (zh) * 2006-12-14 2012-05-09 安斯泰来制药有限公司 用作crth2拮抗剂和抗过敏剂的多环酸化合物
SG11201408324QA (en) 2012-06-12 2015-01-29 Abbvie Inc Pyridinone and pyridazinone derivatives
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
CA3071795A1 (en) 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
US12138274B2 (en) 2018-11-08 2024-11-12 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
AR117929A1 (es) 2019-02-01 2021-09-01 Bayer Ag Compuestos de 1,2,4-triazin-3(2h)-ona
CN111840557A (zh) * 2019-04-28 2020-10-30 中国医学科学院阜外医院 磷酸二酯酶4抑制剂的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
DE19604388A1 (de) * 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19737436A1 (de) * 1997-08-21 1999-02-25 Schering Ag Inhibition der Monozyten-Extravasation
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19915365A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-Derivate
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
DE19932315A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzoylpyridazine

Also Published As

Publication number Publication date
EP1368035A1 (en) 2003-12-10
WO2002072103A1 (en) 2002-09-19
CN1235589C (zh) 2006-01-11
JP2004521928A (ja) 2004-07-22
NO20033541D0 (no) 2003-08-11
HUP0303181A2 (hu) 2004-01-28
US20050070529A1 (en) 2005-03-31
CA2437932A1 (en) 2002-09-19
CN1491112A (zh) 2004-04-21
KR20040012720A (ko) 2004-02-11

Similar Documents

Publication Publication Date Title
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
SE9800836D0 (sv) New Compounds
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60330485D1 (de) Zur behandlung von diabetes
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
NO20055941L (no) Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application